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CD-ROM and via the Internet. The electronic
format allows Cochrane reviews to accommodate
new data as they become available, making the
library a consistently up-to-date source of informa-
tion over time.
Certain abstracts appearing in The Cochrane
Database of Systematic Reviews may be presented in
a simpler, less scientific format than the abstract
presented here to permit greater accessibility to the
public. However, the substance of both versions is
the same. Cochrane reviews are now indexed on
MEDLINE.
If you are interested in conducting a Cochrane
review or contributing to the activities of the Co-
chrane Collaborative Review Group on Peripheral
Vascular Diseases, please contact:
Professor FGR Fowkes
Cochrane Collaborative Review Group on Peri-
pheral Vascular Diseases
Public Health Sciences
University of Edinburgh
Teviot Place
Edinburgh EH8 9AG
Tel.: þ44 (0) 131 650 3220
Fax: þ44 (0) 131 650 6904.
Any comments or criticisms on Cochrane reviews/
abstracts should be made through the comments/
criticisms facility on The Cochrane Library, or by con-
tacting the group at the above address.884/000512+ 04 $32.00/0  2007 Elsevier Ltd. All rights reseAbstracts
Abstract. Compression stockings for preventing
deep vein thrombosis in airline passengers.
Clarke M, Hopewell S, Juszczak E, Eisinga A,
Kjeldstrøm M
The Cochrane Database of Systematic Reviews Pub-
lished in Issue 2, 2006
Background
Air travel might increase the risk of deep vein throm-
bosis (DVT). It has been suggested that wearing
compression stockings might reduce this risk.
Objectives
To assess the effects of wearing compression stockings
versus not wearing them among people travelling on
flights lasting at least four hours.
Search strategy
We searched the Cochrane Peripheral Vascular
Diseases Group’s Specialized Register (last searched
January 2006), the Cochrane Central Register of
Controlled Trials (CENTRAL) (in The Cochrane Library,
Issue 4, 2005), MEDLINE (January 1966 to November
2005), EMBASE (January 1980 to December 2005) and
several other electronic or grey literature sources,
detailed in full in the review. The most recent searches
were done in January 2006.
Selection criteria
Randomized trials of compression stockings versus
no stockings in passengers on flights lasting at leastrved.
513Cochrane Review Abstractsfour hours. Trials in which passengers wore a stock-
ing on one leg but not the other, or those comparing
stockings and another intervention were also
eligible.
Data collection and analysis
At least two authors independently assessed the qual-
ity of each study and extracted data. We sought
additional information from trialists.
Main results
Ten randomized trials (n¼ 2856) were included; nine
(n¼ 2821) compared wearing stockings on both legs
versus not wearing them, and one (n¼ 35) compared
wearing a stocking on one leg for the outbound flight
and on the other leg on the return flight. Of the nine
trials, seven included people judged to be at low or
medium risk (n¼ 1548) and two included high risk
participants (n¼ 1273). All flights lasted at least seven
hours.
Fifty of 2637 participants with follow-up data avail-
able in the trials of wearing stockings on both legs had
a symptomless DVT; three wore stockings, 47 did not
(odds ratio 0.10, 95% confidence interval 0.04 to 0.25,
P< 0.00001). There were no symptomless DVTs in
three trials. No deaths, pulmonary emboli or symp-
tomatic DVTs were reported. Wearing stockings had
a significant impact in reducing oedema (based on
six trials). No significant adverse effects were
reported.
Authors’ conclusions
Airline passengers similar to those in this review can
expect a substantial reduction in the incidence of
symptomless DVT and leg oedema if they wear
compression stockings. We cannot assess the effect
of wearing stockings on death, pulmonary embolus
or symptomatic DVT because no such events occurred
in these trials. Randomized trials to assess these
outcomes would need to include a very large number
of people.
Abstract. Supervised exercise therapy versus non-
supervised exercise therapy for intermittent
claudication
Bendermacher BLW, Willigendael EM, Teijink JAW,
Prins MH
The Cochrane Database of Systematic Reviews Pub-
lished in Issue 2, 2006Background
Although exercise therapy is considered to be of sig-
nificant benefit to people with leg pain (intermittent
claudication), almost half of those affected do not
undertake any exercise therapy.
Objectives
To evaluate the effects of supervised versus non-
supervised exercise therapy on the maximal walking
time or distance for people with intermittent
claudication.
Search strategy
The Cochrane Peripheral Vascular Diseases Group
searched their Specialized Register (last searched
November 2005) and the Cochrane Central Register
of Controlled Trials (CENTRAL) database in The
Cochrane Library (last searched Issue 4, 2005).
In addition, we handsearched the reference lists of
relevant articles for additional trials. There was no
restriction on language of publication.
Selection criteria
Randomized and controlled clinical trials comparing
supervised exercise programs with non-supervised
exercise programs for people with intermittent
claudication.
Data collection and analysis
Two authors (BB and EMW) independently selected
trials and extracted data. One author (BB) assessed
trial quality and this was confirmed by a second
author (MP). For all continuous outcomes we ex-
tracted the number of participants, the mean differ-
ences, and the standard deviation. If data were
available, the standardized mean difference was
calculated using a fixed-effect model.
Main results
We identified twenty-seven trials, of which 19 had to
be excluded because the control group received no
exercise therapy at all. The remaining eight trials in-
volved a total of 319 male and female participants
with intermittent claudication. The follow up ranged
from 12 weeks to 12 months. In general, theEur J Vasc Endovasc Surg Vol 33, May 2007
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cise sessions per week. All trials used a treadmill
walking test as one of the outcome measures. The
overall quality of the included trials was good, though
the trials were all small with respect to the number of
participants, ranging from 20 to 59.
Supervised exercise therapy showed statistically
significant and clinically relevant differences in im-
provement of maximal treadmill walking distance
compared with non-supervised exercise therapy regi-
mens,with an overall effect size of 0.58 (95% confidence
interval 0.31 to 0.85) at three months. This translates to
a difference of approximately 150 meters increase in
walking distance in favor of the supervised group.
Authors’ conclusions
Supervised exercise therapy is suggested to have clini-
cally relevant benefits compared with non-supervised
regimens, which is the main prescribed exercise ther-
apy for people with intermittent claudication. How-
ever, the clinical relevance has not been demonstrated
definitely and will require additional studies with a
focus on the improvements in quality of life.
Abstract. Thrombolytic therapy for pulmonary
embolism
Dong B, Jirong Y, Liu G, Wang Q, Wu T
The Cochrane Database of Systematic Reviews Pub-
lished in Issue 2, 2006
Background
Thrombolytic therapy is usually reserved for patients
with clinically serious or massive pulmonary embo-
lism (PE). Evidence suggests that thrombolytic agents
may dissolve blood clot more rapidly than heparin
and might reduce the death rate associated with PE.
However, there are still concerns about the possible
risk of adverse effects of thrombolytic therapy, such
as major or minor haemorrhages.
Objectives
To assess the effectiveness and safety of thrombolytic
therapy in patients with acute PE.
Search strategy
We sought trials through the Cochrane Peripheral
Vascular Diseases Group’s Specialized Register (lastEur J Vasc Endovasc Surg Vol 33, May 2007searched January 18, 2006), the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL) (The Cochrane
Library Issue 1, 2006), MEDLINE (January 1966 to
December 2004), EMBASE, CINAHL, LILACS and
SCISEARCH (all November 2004). We also searched
individual trial collections and private databases,
along with bibliographies of relevant articles. Rele-
vant medical journals were handsearched. The most
recent search was on February 6, 2006.
Selection criteria
Randomized controlled trials (RCTs) that compared
thrombolytic therapy with placebo or heparin or
surgical intervention in patients with acute PE. We
did not include trials comparing two different throm-
bolytic agents or different doses of the same thrombo-
lytic drug.
Data collection and analysis
Two authors (DB and WQ) assessed the eligibility and
quality of trials and extracted data.
Main results
Results were similar between thrombolytics com-
pared with heparin alone or placebo and heparin in
terms of:
(a) death rate: odds ratio (OR) 0.89; 95% confidence
interval (CI) 0.45 to 1.78;
(b) recurrence of pulmonary embolism: OR 0.63; 95%
CI 0.33 to 1.20;
(c) major haemorrhagic events: OR 1.61; 95% CI 0.91
to 2.86;
(d) minor haemorrhagic events: OR 1.98; 95% CI 0.68
to 5.75.
We found no trials comparing thrombolytic ther-
apy to surgical intervention.
Using recombinant tissue-type plasminogen acti-
vator (rt-PA) and heparin together compared to hep-
arin alone appeared to reduce the need for further
treatment for in-hospital events (OR 0.35; 95% CI
0.17 to 0.71).
Thrombolytics improved haemodynamic out-
comes, perfusion lung scanning, pulmonary angio-
gram assessment and echocardiograms to a greater
extent than heparin alone.
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We cannot conclude whether thrombolytic therapy is
better than heparin for pulmonary embolism based
on the limited evidence found. More double-blind
RCTs, with subgroup analysis of patients presenting
with haemodynamically stable acute pulmonary
embolism compared to those patients with a haemo-
dynamic unstable condition, are required.
Abstract. Prevention of infection in arterial
reconstruction
Stewart A, Eyers PS, Earnshaw JJ
The Cochrane Database of Systematic Reviews Pub-
lished in Issue 3, 2006
Background
Arterial reconstructions with prosthetic graft mate-
rials or vein are susceptible to infection with a resul-
tant high patient mortality and risk of limb loss. To
reduce the risk of infection effective perioperative
measures are essential.
Objectives
To determine the effectiveness of perioperative strate-
gies to prevent infection in patients undergoing
peripheral arterial reconstruction.
Search strategy
We searched the Cochrane Peripheral Vascular Dis-
eases Group trials register (last searched May 2006)
and the Cochrane Central Register of Controlled Trials
(CENTRAL) (last searched Issue 2, 2006), and refer-
ence lists of relevant articles.
Selection criteria
All randomized controlled trials (RCTs) evaluating
measures intended to reduce or prevent infection in
arterial surgery.Data collection and analysis
Two authors (AS and PSE) independently selected
and assessed the quality of included trials. Relative
risk was used as a measure of effect for each dicho-
tomous outcome.
Main results
Thirty-five RCTs were included. Of these, 23 were
trials of prophylactic systemic antibiotics, three of
rifampicin-bonded grafts, three of preoperative skin
antisepsis, two of suction wound drainage, two of
minimally invasive in situ bypass techniques, and in-
dividual trials of intraoperative glove change and
wound closure techniques. Wound infection or early
graft infection outcomes were recorded in all trials.
Only two trials, both of rifampicin bonding, followed
up graft infection outcomes to two years.
Trials of antibiotics versus placebo were of highest
quality with six double-blind studies of the ten
included.
Prophylactic systemic antibiotics reduced the risk
of wound infection (Relative Risk (RR) 0.25, 95% Con-
fidence Interval (CI) 0.17 to 0.38) and early graft infec-
tion in a fixed-effect model (RR 0.31, 95% CI 0.11 to
0.85, P¼ 0.02). Antibiotic prophylaxis for greater
than 24 hours appears to be of no added benefit (RR
1.28, 95% CI 0.82 to 1.98).
There was no evidence that prophylactic rifampicin
bonding to dacron grafts reduced graft infection at
either one month (RR 0.63, 95% CI 0.27 to 1.49) or
two years (RR 1.05, 95% CI 0.46 to 2.40).
There was no evidence of a beneficial or detrimen-
tal effect on rates of wound infection with suction
groin-wound drainage (RR 0.96 95% CI 0.50 to 1.86)
or of any benefit from a preoperative bathing or
shower regimen with antiseptic agents over unmedi-
cated bathing (RR 0.97, 95% CI 0.70 to 1.36).
Authors’ conclusions
There is clear evidence of the benefits of prophylactic
broad spectrum antibiotics. Many other interventions
intended to reduce the risk of infection in arterial
reconstruction lack evidence of effectiveness.
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